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Introduction
Intermittent hypoxia (IH) is one of the major components of obstructive sleep apnea syndrome [1] [2] . It has been extensively demonstrated both in animals [3] and humans [4] that IH is a determinant of cardiovascular morbidity. Surprisingly, a decline in mortality rates with age has been observed in OSA patients [5] , which suggests a possible cardiovascular protection by IH [6] . There are several described differences between sustained hypoxia (SH) and IH. Notably, it has been observed a differential gene activation under IH or SH [7] . We have thus studied the acute effects of a model mimicking the OSA consequences as previously described [8] .
Hypoxic preconditioning (PC), like ischemic PC [9] can provide delayed protection against ischemia-reperfusion injury [10, 11] . IH for 4 hrs with 10% O 2 induces cardioprotection illustrated by a reduction of infarct size in isolated rat heart [8] .
The cellular pathways and mechanisms involved in delayed ischemic PC are well documented. In particular, the first demonstration of a role for PKC in delayed PC, was from Yamashita and colleagues who demonstrated that staurosporine, a PKC inhibitor, could prevent in vitro the acquisition of this phenomenon in hypoxic preconditioned rat cardiomyocytes [12] . Subsequently, it was observed in the rabbit, that the delayed protection following ischemic PC is abolished in vivo by chelerythrine (Chel), another PKC inhibitor [13] . The first aim of the present study was to assess whether the IH-induced reduction in infarct size is mediated and/or triggered by PKC (i.e.: chelerythrine treatment before sustained ischemia or prior to hypoxic PC).
Recent studies have revealed that phosphatidylinositol 3-kinase/protein kinase B (PI3K-Akt) pathway is involved in delayed myocardial PC as a triggering actor. Notably, wortmannin (WOT), a PI3K inhibitor, administration before ischemic PC prevents the reduction in infarct size in the rabbit [14] . Moreover, in a mice model, WOT administration before pharmacological PC abolished its antiapoptotic effect [15] . Therefore, the second aim of this study was to test whether PI3K is involved in triggering the myocardial protection induced by IH.
The mitogen-activated protein kinases (MAPK) mediate various cellular responses including proliferation, differentiation and adaptation to stress [16] . Two major MAP kinase families have been studied in the triggering phase of PC: the p38 MAPK and the extracellular signalregulated kinase (Erk1/2). The p38 MAPK signalling pathways has been shown to be implicated in both delayed ischemic [17] and pharmacological [18, 19] PC. Meanwhile, the Erk1/2 cascade has been involved in delayed hypoxic [20] and pharmacological PC [21] .
Taken together, these findings led us to assess whether p38 MAPK and/or Erk1/2 activation participate to the IH-induced delayed cardioprotection.
Methods
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Experiments were conducted on adult male Wistar rats (weight range 330-380 g) from Elevage Janvier (France) housed in controlled conditions and provided with standard rat chow.
Intermittent hypoxia protocol
Rats were exposed to intermittent hypoxia (IH) as previously described [8] . Briefly, rats were placed in Plexiglas chambers (length 28 cm, diameter 10 cm, volume 2.2 l). A timed solenoid valve was used to distribute nitrogen and air to each chamber. IH chambers were flushed with an air-nitrogen mixture for 40 sec to achieve hypoxia (10% O 2 ) followed by 20 sec of compressed air to restore normoxia (21% O 2 ). This 1-min cycle was repeated for 4 hrs. In parallel, compressed air at the same flow rate was distributed to sham chambers in order to submit sham animals to similar noise and airflow disturbances. The level of O 2 in the chambers was controlled throughout the hypoxia protocol using a gas analyzer (model ML206, AD Instruments).
Isolated rat heart preparation
Twenty-four hours after IH, the rats were anesthetized with 60 mg/kg i.p. sodium pentobarbital and treated with heparin (500 UI/kg, i.v.). Hearts were rapidly excised and briefly placed in cold (4°C) Krebs-Henseleit (KH) buffer before being mounted on the Langendorff apparatus via the aorta. The hearts were then retrogradely perfused at constant pressure (75 mmHg), with KH buffer containing in mM: NaCl 118.0, KCl 4.7, CaCl 2 2.5, KH 2 PO 4 1.2, MgSO 4 1.2, NaHCO 3 25.2 and glucose 11.0. The perfusion medium was continuously gassed with 95% O 2 and 5% CO 2 and maintained at 37 °C and pH 7.4 as previously described [8] . A water-filled latex balloon (Hugo Sachs, n°4), connected to a pressure transducer, was inserted into the left ventricular cavity via the left atrium for pressure recording. Left ventricular end-diastolic pressure (LVEDP) was adjusted between 5-10 mmHg. Myocardial temperature was measured by a thermoprobe inserted into the left atrium and was maintained constant at 37°C. After 20 min of stabilization, no-flow global ischemia was induced by stopping the perfusion for 30 min. The hearts were kept at constant humidity and temperature (37°C) throughout ischemia and were thereafter reperfused for 120 min.
Coronary flow (CF), expressed in ml/min/g, was measured periodically during the ischemiareperfusion procedure, by collecting the effluent. Heart rate (HR), LVEDP, left ventricular developed pressure (LVDP = difference between left ventricular systolic pressure and LVEDP) and dP/dt max (maximal rate of left ventricular pressure rise) were recorded continuously (PC Lab 4S, AD Instruments).
Treatment groups
Twenty-four hours prior to global ischemia-reperfusion, all rats were submitted to either normoxia (N, 21% O 2 ) or intermittent hypoxia (IH, 10% O 2 ) during 4 hrs, and randomised into one of 16 groups (Figure 1 Groups N (n=8) and IH (n=8) were only submitted to normoxic or IH exposure.
Groups N Chel1 (n=7) and IH Chel1 (n=7) were infused with chelerythrine 5 µM [23] , 10 min before ischemia.
Groups N dmso 10 (n=7), IH dmso 10 (n=9), N WOT (n=9), IH WOT (n=7), N Chel2 (n=9) and IH Chel2 (n=8), were injected (i.p.) with dmso 1%, wortmannin 15 µg/kg [24] and chelerythrine 5 mg/kg [25] respectively, 10 min prior to N or IH.
Groups N dmso 30 (n=7), IH dmso 30 (n=8), N SB (n=8), IH SB (n=8), N PD (n=8) and IH PD (n=8), were injected (i.p.) with dmso 1%, SB203580 1 mg/kg [21] and PD98059 0,5 mg/kg [18] respectively, 30 min prior to N or IH.
Infarct size
At the end of the ischemia-reperfusion protocol, the atria were removed and the hearts were frozen at -20°C for 10 min. They were then cut into 2-mm transverse sections from apex to base (6-7 slices/heart). Once thawed, the slices were incubated at 37°C with 1% triphenyltetrazolium chloride in phosphate buffer (pH 7.4) for 10 min, fixed in 10% formaldehyde solution and photographed. Areas of infarcted tissue were measured using a computerized planimetric technique (Image Tool for Windows) and expressed as a percentage of total ventricular area (I/V).
Western blotting
To determine whether hypoxic PC was associated with an activation of Akt, p38 and Erk1/2 MAP kinases, hearts from additional animals (n=4 in each group) submitted to normoxia or IH were harvested 24 hrs later as described above. Hearts were homogenized in lysis buffer and centrifugated at 13 000 rpm for 20 minutes to remove nuclei and debris. The supernatant was collected and protein concentration was determined by the Pierce assay (Perbio Science France, Bezons, France). Proteins were loaded at 50-70 µg/lane. Phosphorylated states of Akt (phospho Akt; Ser 473), p38 MAPK (phospho p38; Thr180/Tyr182) and Erk1/2 (phosphoErk; Thr202/Tyr204) as well as total levels of Akt, p38 MAPK, Erk1/2 and GAPDH were analysed by 10% SDS/PAGE with antibodies from Cell Signaling Technology (Ozyme, Saint Quentin Yvelines, France) (except for GAPDH from Santa Cruz Technology, Tebu-Bio, Le phosphorylated proteins were normalised to total protein levels assessed in the same samples and under the same conditions on separate membrane. Relative densitometry was computerized (Image J software).
Exclusion criteria
Only hearts with CF ≤ 20 ml/min/g and LVDP > 70 mmHg at the end of the stabilization period were included in this study.
Chemicals
Chelerythrine, wortmannin and PD98059 were from Calbiochem (VWR International, Fontenay sous Bois, France), dmso from Sigma-Aldrich (Saint Quentin Fallavier, France) and SB203580 was synthesised by Dr A. Boumendjel (DPM, UMR 5063 UJF/CNRS, Université Grenoble I, France).
Statistical analysis
Hemodynamic and infarct size data are presented as mean ± standard error of the mean (s.e.m.). Infarct size values and hemodynamic data were compared using two-way analyses of variance (ANOVA), with exposure and treatment corresponding to each factor. Post-hoc multiple comparisons were performed using Bonferroni tests. For blot analysis groups were compared using t-tests. Statistical significance was set at p<0.05. and functional recovery (Table 3) . Vehicle (dmso 1%) injection 10 min prior to N or IH had no effect per se ( Figure 3b and Table 2 (Table 3 ) between hypoxic and normoxic animals. Vehicle (dmso 1%) administration 30 min prior to N or IH had no effect per se ( Figure 4 and Table 3 
Discussion
This study provides the first demonstration that IH-induced delayed protection against myocardial infarction is triggered by p38 MAPK and Erk1/2 but not by PI3K and PKC. PKC, however, seems to play a role as a mediator of hypoxic PC. This is based on the observation that: 1) chelerythrine infusion before ischemia blocked the IH-induced cardioprotection, 2) wortmannin or chelerythrine injection prior to IH did not modify the cardioprotective response, 3) the MAP kinase inhibitor SB203580 and the MEK inhibitor PD98059, injected prior to IH, blocked the IH-induced cardioprotection and 4) a significant phosphorylation of both p38 MAPK and Erk1/2 was observed in the myocardium 24 hrs after IH.
In this study, we investigated the role of PKC in triggering and mediating IH-induced PC. We showed that IH-induced cardioprotection was abolished when chelerythrine was infused before ischemia. This is in accordance with other studies which have shown, using chelerythrine, a role for PKC in mediating delayed ischemic [13] and pharmacological [26] PC. However, the implication of other kinases can not be excluded since chelerythrine has been reported to affect some of them [27] . Furthermore, activation of PKC after ischemic PC is isoform selective. Notably, the epsilon isoform appears to be responsible for the development of delayed cardioprotection in the rabbit [28] . Thus assessment of the PKC isoform relevant to protection induced by IH should be of interest.
In a previous study [8] , we suggested involvement of the ATP-sensitive potassium (K ATP ) channel, as mediator of protection, in delayed hypoxic PC. Protein kinase-catalyzed phosphorylation is an important mechanism by which the activity of ion channels, including the K ATP channel, can be controlled [29] . There is evidence suggesting the importance of PKC in activating K ATP channels during the protective mechanism of delayed pharmacological PC [30] . Thus an interaction between PKC and K ATP in the IH-induced cardioprotection could be possible and this could be investigated in measuring mitochondrial matrix redox potential (an index of mitoK ATP channel activity) with and without a PKC inhibitor. In our previous study [8] we also demonstrated a role for NO synthase (NOS) in mediating IH-induced PC since a non specific inhibitor of NOS, L-NAME, abolished the delayed cardioprotection. We can suggest in the study presented here that PKC could play a role on NOS expression. Indeed, it is well-documented in ischemic or pharmacological PC, that activation of PKC-epsilon triggers a signalling cascade that leads to the binding of the transcription factor NF-B to the inducible NOS (iNOS) promoter. This results in synthesis of new iNOS proteins, which leads to a preconditioned phenotype [31] .
On the other hand, we showed that chelerythrine injection prior to IH did not modify IHinduced delayed cardioprotection. This is, to our knowledge, the first demonstration that the triggering phase of delayed PC is independent of PKC activation. However, this is consistent with previous studies focussing on early ischemic PC. The first one is by Przyklenk and colleagues who observed that PKC inhibition did not alter the infarct size reduction achieved by PC in the anesthetized open-chest dog [22] . Moreover, the work of Yang et al supports the idea that in rabbit heart, the trigger phase of PC does not require kinase activity, while the mediation phase is dependent on kinase phosphorylation [32] .
The PI3K signalling pathway has been shown to confer protection against ischemiareperfusion injury via the activation of Akt [33] . Kis and colleagues have shown that WOT blocked delayed ischemic PC and prevented Akt phosphorylation in vivo in the rabbit [14] . In contrast, we observed that WOT, even if preventing Akt phosphorylation, did not block the IH-induced PC. This discrepancy should be due to species differences, to the PC stimulus or to the WOT dosage used. Therefore, we can suggest that Akt phosphorylation is not involved in IH PC in the rat. This is also, to our knowledge, the first demonstration that the triggering phase of delayed PC is independent of PI3K activation. However, this is consistent with previous studies focussing on early pharmacological PC. Notably, the adenosine-induced PC was shown to be insensitive to wortmannin [34, 35] .
Several studies have reported the implication of p38 MAPK in delayed pharmacological PC [17, 18] . In accordance, we observed that SB203580, a p38 MAPK inhibitor, abolished the cardioprotection afforded by IH.
There is also evidence that hypoxia can activate p38 MAPK in several tissues including the heart [36, 37] . Notably, p38 MAP kinase phosphorylation was reported 24 hrs after delayed pharmacological PC [38] . This is also confirmed in our study since we observed a myocardial activation of p38 MAPK 24 hrs after IH.
Since SB203580 has been reported to also inhibit the stress activated protein kinase, SAPK/JNK [39] , we cannot rule out a role of this kinase in the PC conferred by IH.
Moreover, controversy exists as to the beneficial-detrimental role of p38 MAPK in cardioprotection [40] . Indeed persistent activation of p38 MAPK during ischemia has been shown to be deleterious for cells [41, 42] . This dual role may be explained by differential function of p38 subfamily members. Thus, it should be further investigated which p38 isoform is involved in the IH-induced delayed PC. Finally, the causal relationship between p38 MAPK phosphorylation and IH-induced cardioprotection should be assessed by studying the effect of SB203580 on p38 MAPK phosphorylation.
In contrast to the numerous reports involving p38 MAPK in delayed PC, there are few studies on Erk1/2, another member of the MAPK family. Two studies showed that PD98059 abolished delayed pharmacological PC [18, 21] . Our study is the first to show that PD98059 blocked the IH-induced PC. Additionally, we observe an increase in Erk1/2 phosphorylation phosphorylation 18 hrs after hypoxia [35] . Like for p38 MAPK, the causal relationship between Erk1/2 phosphorylation and cardioprotection needs further investigation. Another limitation of our study is the use of inhibitors that are not fully specific (chelerythrine, SB203580), even if we used them at a concentration demonstrated in literature to have an effect in the rat.
One potential limitation of this study is that only one time point was chosen to examine the phosphorylation level of several protein kinases induced by IH. It would be important to examine the time course of phosphorylation/dephosphorylation of these protein kinases in the setting of IH PC and this is the subject of a future investigation.
In summary, this study shows that PKC, as a mediator, and p38 MAPK and Erk1/2, as triggers, participate to the IH-induced delayed PC. In a putative linear pathway linking these various actors of hypoxic PC, we would thus expect PKC to be downstream from MAP kinases because treatment with the p38 MAPK and Erk1/2 inhibitors abolished cardioprotection when administered before IH and treatment with chelerythrine only abolished cardioprotection when given before the prolonged ischemic period. Then, after a 20 min stabilization period, a 30-min no-flow global ischemia followed by a 120-min reperfusion was performed in vitro. Chelerythrine was infused 10 min before ischemia (Chel1). In other groups, wortmannin (WOT), chelerythrine (Chel2) and their vehicle (dmso 10) were injected intraperitoneally 10 min prior to normoxic or hypoxic stress. 
